Leaflet EMEND 125mg / 80mg capsules
Indicated for: chemotherapy-induced nausea and vomiting
Route of administration: oral
Substance: aprepitant (antiemetic)
ATC: A04AD12 (Alimentary tract and metabolism | Antiemetics and antinauseants | Other antiemetics)
Aprepitant is a neurokinin-1 (NK1) receptor antagonist used in the prevention of chemotherapy-induced or postoperative nausea and vomiting. It works by blocking NK1 receptors in the central nervous system, thereby preventing the effects of substance P, a neurotransmitter involved in the vomiting reflex.
Aprepitant is administered orally, usually in combination with other antiemetic medications such as corticosteroids and 5-HT3 receptor antagonists. It is commonly used in chemotherapy regimens with high emetogenic potential.
Common side effects include fatigue, constipation, diarrhea, and loss of appetite. In rare cases, allergic reactions or elevated liver enzymes may occur.
Aprepitant is an important therapeutic option for patients undergoing chemotherapy, helping to improve treatment tolerance and maintain their quality of life.
General data about EMEND 125mg / 80mg
- Substance: aprepitant
- Date of last drug list: 01-06-2026
- Commercial code: W64642001
- Concentration: 125mg / 80mg
- Pharmaceutical form: capsules
- Quantity: 1
- Product type: original
- Price: 92.68 RON
- Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Concentrations available for aprepitant
- 125mg
- 125mg/80mg
- 40mg
- 80mg
